Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Capecitabine, Neratinib in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Canada:
NERLYNX (neratinib) is indicated in combination with capecitabine for the treatment of patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.